JPWM
KRYS icon

Jamison Private Wealth Management’s Krystal Biotech KRYS Stock Holding History

Jamison Private Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-150
Closed -$27.3K – 341
2024
Q3 		$27.3K Hold
150
– – ﹤0.01% 285
2024
Q2 		$27.5K Buy
+150
New +$25.2K ﹤0.01% 276

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jamison Private Wealth Management's KRYS Position: Q4 2024 in Review

Jamison Private Wealth Management sold out of Krystal Biotech (KRYS) in Q4 2024, closing a stake of 150 shares — an estimated $27.3K sold.

Jamison Private Wealth Management first reported a position in KRYS in Q2 2024 and held it in 2 quarters. The position peaked at $27.5K in Q2 2024. 264 funds tracked by Wall St. Rank hold KRYS as of Q4 2024.

  • Jamison Private Wealth Management reported no remaining Krystal Biotech position as of Q4 2024 after selling out during the quarter.
  • Jamison Private Wealth Management sold 150 Krystal Biotech shares in Q4 2024, an estimated $27.3K.
  • Jamison Private Wealth Management first reported a position in Krystal Biotech in Q2 2024 and held it in 2 quarters.
  • Jamison Private Wealth Management's Krystal Biotech position peaked at $27.5K in Q2 2024.
  • 264 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2024.

Based on Jamison Private Wealth Management's 13F filing for Q4 2024, filed 21 Jan 2025.